A. Ward, G. Molenaers, C. Colosimo, and A. Berardelli, Clinical value of botulinum toxin in neurological indications, European Journal of Neurology, vol.6, issue.4, pp.20-26, 2006.
DOI : 10.1046/j.1468-1331.2001.00040.x

A. Brashear, M. Gordon, E. Elovic, V. Kassicieh, C. Marciniak et al., Intramuscular Injection of Botulinum Toxin for the Treatment of Wrist and Finger Spasticity after a Stroke, New England Journal of Medicine, vol.347, issue.6, pp.395-400, 2002.
DOI : 10.1056/NEJMoa011892

K. Aoki, Review of a Proposed Mechanism for the Antinociceptive Action of Botulinum Toxin Type A, NeuroToxicology, vol.26, issue.5, pp.785-93, 2005.
DOI : 10.1016/j.neuro.2005.01.017

S. Mense, Neurobiological basis for the use of botulinum toxin in pain therapy, Journal of Neurology, vol.251, issue.0, pp.1-7, 2004.
DOI : 10.1007/s00415-004-1102-z

H. Handwerker and . Nociceptors, Chapter 3 Nociceptors: neurogenic inflammation, Handbook of clinical neurology Pain, F, vol.81, pp.23-33, 2006.
DOI : 10.1016/S0072-9752(06)80007-2

H. Ishikawa, Y. Mitsui, T. Yoshitomi, and K. Mashimo, Presynaptic Effects of Botulinum Toxin Type A on the Neuronally Evoked Response of Albino and Pigmented Rabbit Iris Sphincter and Dilator Muscles, Japanese Journal of Ophthalmology, vol.44, issue.2, pp.106-115, 2000.
DOI : 10.1016/S0021-5155(99)00197-5

J. Purkiss, M. Welch, S. Doward, and K. Foster, Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms, Biochemical Pharmacology, vol.59, issue.11, pp.1403-1406, 2000.
DOI : 10.1016/S0006-2952(00)00260-4

F. Meunier, C. Colasante, L. Faille, M. Gastard, and J. Molgo, Upregulation of calcitonin gene-related peptide at mouse motor nerve terminals poisoned with botulinum type-A toxin, Pfl??gers Archiv European Journal of Physiology, vol.8, issue.2, pp.297-305, 1996.
DOI : 10.1007/BF02346386

P. Durham, C. Rand, and R. Cady, Regulation of Calcitonin Gene-Related Peptide Secretion From Trigeminal Nerve Cells by Botulinum Toxin Type A: Implications for Migraine Therapy, Headache: The Journal of Head and Face Pain, vol.19, issue.suppl 1, pp.35-42, 2004.
DOI : 10.1111/j.1526-4610.2004.04007.x

M. Cui, S. Khanijou, J. Rubino, and K. Aoki, Subcutaneous administration of botulinum toxin A reduces formalin-induced pain, Pain, vol.107, issue.1, pp.125-133, 2004.
DOI : 10.1016/j.pain.2003.10.008

C. Morenilla-palao, R. Planells-cases, N. Garcia-sanz, and A. Ferrer-montiel, Regulated Exocytosis Contributes to Protein Kinase C Potentiation of Vanilloid Receptor Activity, Journal of Biological Chemistry, vol.279, issue.24, pp.25665-25672, 2004.
DOI : 10.1074/jbc.M311515200

S. Luvisetto, S. Marinelli, F. Lucchetti, and F. Marchi, Botulinum neurotoxins and formalin-induced pain: Central vs. peripheral effects in mice, Brain Research, vol.1082, issue.1, pp.124-131, 2006.
DOI : 10.1016/j.brainres.2006.01.117

L. Bach-rojecky, M. Relja, and Z. Lackovic, Botulinum toxin type A in experimental neuropathic pain, Journal of Neural Transmission, vol.112, issue.2, pp.215-224, 2005.
DOI : 10.1007/s00702-004-0265-1

S. Luvisetto, S. Marinelli, S. Cobianchi, and F. Pavone, Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain, Neuroscience, vol.145, issue.1, pp.1-4, 2007.
DOI : 10.1016/j.neuroscience.2006.12.004

H. Park, Y. Lee, J. Lee, C. Park, and D. Moon, Les effets de la toxine botulique a sur ??allodynie m??canique et ??allodynie au froid chez un mod??le de douleur neuropathique chez le rat, Canadian Journal of Anesthesia/Journal canadien d'anesth??sie, vol.43, issue.1, pp.470-77, 2006.
DOI : 10.1007/BF03022619

M. Cline, J. Ochoa, and H. Torebjork, CHRONIC HYPERALGESIA AND SKIN WARMING CAUSED BY SENSITIZED C NOCICEPTORS, Brain, vol.112, issue.3, pp.621-668, 1989.
DOI : 10.1093/brain/112.3.621

H. Fields, M. Rowbotham, and R. Baron, Postherpetic Neuralgia: Irritable Nociceptors and Deafferentation, Neurobiology of Disease, vol.5, issue.4, pp.209-236, 1998.
DOI : 10.1006/nbdi.1998.0204

K. Petersen, H. Fields, J. Brennum, P. Sandroni, and M. Rowbotham, Capsaicin evoked pain and allodynia in post-herpetic neuralgia, Pain, vol.88, issue.2, pp.125-158, 2000.
DOI : 10.1016/S0304-3959(00)00311-0

K. Hempenstall, T. Nurmikko, R. Johnson, A. Hern, R. Rice et al., Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review, PLoS Medicine, vol.2, issue.7, p.164, 2005.
DOI : 10.1371/journal.pmed.0020164.t502

H. Kehlet, T. Jensen, and C. Woolf, Persistent postsurgical pain: risk factors and prevention, The Lancet, vol.367, issue.9522, pp.1618-1643, 2006.
DOI : 10.1016/S0140-6736(06)68700-X

N. Attal, M. Haanpaa, P. Hansson, and T. Jensen, EFNS guidelines on pharmacological treatment of neuropathic pain, European Journal of Neurology, vol.32, issue.2, pp.1153-69, 2006.
DOI : 10.1053/eujp.2001.0316

N. Finnerup, M. Otto, and H. Mcquay, Algorithm for neuropathic pain treatment: An evidence based proposal, Pain, vol.118, issue.3, pp.289-305, 2005.
DOI : 10.1016/j.pain.2005.08.013

G. Hall, D. Carroll, D. Parry, and H. Mcquay, Epidemiology and treatment of neuropathic pain: The UK primary care perspective, Pain, vol.122, issue.1, pp.156-62, 2006.
DOI : 10.1016/j.pain.2006.01.030

C. Argoff, A Focused Review on the Use of Botulinum Toxins for Neuropathic Pain, The Clinical Journal of Pain, vol.18, issue.Supplement, pp.177-81, 2002.
DOI : 10.1097/00002508-200211001-00010

B. Freund and M. Schwartz, Subcutaneous BTX-A in the treatment of neuropathic pain: a pilot study. Presented at the 38th Interagency Botulism Research Coordinating meeting, pp.292356-292357, 2001.

B. Jabbari, N. Maher, and M. Difazio, Botulinum Toxin A Improved Burning Pain and Allodynia in Two Patients With Spinal Cord Pathology, Pain Medicine, vol.4, issue.2, pp.206-210, 2003.
DOI : 10.1046/j.1526-4637.2003.03013.x

H. Liu, S. Tsai, M. Kao, and J. Hu, Botulinum Toxin A Relieved Neuropathic Pain in a Case of Post-Herpetic Neuralgia, Pain Medicine, vol.7, issue.1, pp.89-91, 2006.
DOI : 10.1111/j.1526-4637.2006.00100.x

M. Naumann, P. Flachenecker, E. Brocker, K. Toyka, and K. Reiners, Botulinum toxin for palmar hyperhidrosis, The Lancet, vol.349, issue.9047, p.252, 1997.
DOI : 10.1016/S0140-6736(05)64861-1

N. Attal, J. Rouaud, L. Brasseur, M. Chauvin, and D. Bouhassira, Systemic lidocaine in pain due to peripheral nerve injury and predictors of response, Neurology, vol.62, issue.2, pp.218-243, 2004.
DOI : 10.1212/01.WNL.0000103237.62009.77

M. Wallace, M. Rowbotham, N. Katz, and R. Dworkin, A randomized, double-blind, placebo-controlled trial of a glycine antagonist in neuropathic pain, Neurology, vol.59, issue.11, pp.1694-700, 2002.
DOI : 10.1212/01.WNL.0000036273.98213.34

¡. Cleeland, C. Ryan, and K. , Pain assessment: global use of the Brief Pain Inventory, Ann Acad Med Singapore, vol.23, pp.129-167, 1994.

D. Ducreux, N. Attal, F. Parker, and D. Bouhassira, Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia, Brain, vol.129, issue.4, pp.129-963, 2006.
DOI : 10.1093/brain/awl016

D. Bouhassira, N. Attal, J. Fermanian, and M. Chaar, Development and validation of the Neuropathic Pain Symptom Inventory, Development and validation of the Neuropathic Pain Symptom Inventory, pp.248-57, 2004.
DOI : 10.1016/j.pain.2003.12.024

A. Zigmond and R. Snaith, The Hospital Anxiety and Depression Scale, Acta Psychiatrica Scandinavica, vol.141, issue.6, pp.361-70, 1983.
DOI : 10.1111/j.1600-0447.1983.tb09716.x

P. Gazerani, C. Staahl, A. Drewes, and L. Arendt-nielsen, The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization, Pain, vol.122, issue.3, pp.315-340, 2006.
DOI : 10.1016/j.pain.2006.04.014

V. Tugnoli, J. Capone, R. Eleopra, and R. Quatrale, Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin, Pain, vol.130, issue.1, pp.76-83, 2007.
DOI : 10.1016/j.pain.2006.10.030

W. Blersch, W. Schulte-mattler, S. Przywara, and A. May, Botulinum toxin A and the cutaneous nociception in humans: A prospective, double-blind, placebo-controlled, randomized study, Journal of the Neurological Sciences, vol.205, issue.1, pp.59-63, 2002.
DOI : 10.1016/S0022-510X(02)00313-1

H. Krämer, C. Angerer, F. Erbguth, M. Schmelz, and F. Birklein, Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin, Journal of Neurology, vol.250, issue.2, pp.188-193, 2003.
DOI : 10.1007/s00415-003-0971-x

W. Schulte-mattler, O. Opatz, W. Blersch, and A. May, Botulinum toxin A does not alter capsaicin-induced pain perception in human skin, Journal of the Neurological Sciences, vol.260, issue.1-2, pp.38-42, 2007.
DOI : 10.1016/j.jns.2007.03.023

T. Sycha, D. Samal, B. Chizh, and S. Lehr, A Lack of Antinociceptive or Antiinflammatory Effect of Botulinum Toxin A in an Inflammatory Human Pain Model, Anesthesia & Analgesia, vol.102, issue.2, pp.509-525, 2006.
DOI : 10.1213/01.ane.0000194447.46763.73

B. Voller, T. Sycha, B. Gustorff, and L. Schmetterer, A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A, Neurology, vol.61, issue.7, pp.940-944, 2003.
DOI : 10.1212/01.WNL.0000086374.92906.6A

D. Ranoux, C. Gury, J. Fondarai, J. Mas, and M. Zuber, Respective potencies of Botox and Dysport : a double-blind, randomized, cross-over study in cervical dystonia, J Neurol Neurosurg Psychiatry, vol.72, pp.459-462, 2002.

M. Dong, F. Yeh, W. Tepp, C. Dean, and E. Johnson, SV2 Is the Protein Receptor for Botulinum Neurotoxin A, Science, vol.312, issue.5773, pp.592-598, 2006.
DOI : 10.1126/science.1123654

N. Attal and D. Bouhassira, Mechanisms of pain in peripheral neuropathy, Acta Neurologica Scandinavica, vol.75, pp.12-24, 1999.
DOI : 10.1111/j.1600-0404.1999.tb07386.x

D. Bouhassira, M. Lanteri-minet, N. Attal, and B. Laurent, Touboul C Prevalence of chronic pain with neuropathic characteristics in the general population, Pain, 2007.

N. Torrance, B. Smith, M. Bennett, and A. Lee, The Epidemiology of Chronic Pain of Predominantly Neuropathic Origin. Results From a General Population Survey, The Journal of Pain, vol.7, issue.4
DOI : 10.1016/j.jpain.2005.11.008

M. Jensen, M. Chodroff, and R. Dworkin, The impact of neuropathic pain on health-related quality of life: Review and implications, Neurology, vol.68, issue.15, pp.1178-82, 2007.
DOI : 10.1212/01.wnl.0000259085.61898.9e

B. Smith, N. Torrance, M. Bennett, and A. Lee, Health and Quality of Life Associated With Chronic Pain of Predominantly Neuropathic Origin in the Community, The Clinical Journal of Pain, vol.23, issue.2, pp.143-152, 2007.
DOI : 10.1097/01.ajp.0000210956.31997.89

R. Dworkin, O. Connor, A. Backonja, M. Farrar, and J. , Pharmacologic management of neuropathic pain: Evidence-based recommendations, Pain, vol.132, issue.3, pp.237-51, 2007.
DOI : 10.1016/j.pain.2007.08.033

J. Vadoud-seyedi and T. Simonart, Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study, British Journal of Dermatology, vol.50, issue.5, pp.986-89, 2007.
DOI : 10.1159/000076482